Trazodone and Venlafaxine-Associated Tardive Dyskinesia Risk

Medication Risk Profiles

• Trazodone, classified as a mood-stabilizing drug, has a lower risk profile for movement disorders compared to typical antipsychotics, which can cause tardive dyskinesia in up to 50% of elderly patients after 2 years of continuous use, according to the American Academy of Family Physicians 1, 3
• Unlike typical antipsychotics, trazodone's risk of tardive dyskinesia appears to be lower but still present, as noted by the American Academy of Family Physicians 1, 2

Clinical Implications and Monitoring

• Regular assessment for abnormal movements should be conducted when patients are taking either trazodone or venlafaxine, as recommended by the American Academy of Child and Adolescent Psychiatry 4
• The Abnormal Involuntary Movement Scale (AIMS) is recommended for monitoring at baseline and then every 3-6 months for patients on medications with tardive dyskinesia risk, according to the American Academy of Child and Adolescent Psychiatry 4, 5
• Early detection is crucial as there is no specific treatment for tardive dyskinesia other than discontinuing the medication, as noted by the American Academy of Child and Adolescent Psychiatry 4

Balancing Risk and Benefit

• The risk of tardive dyskinesia should not outweigh potential benefits in patients who genuinely need these medications for psychiatric stability, according to the American Academy of Child and Adolescent Psychiatry 4
• Informed consent regarding this potential adverse effect is necessary, as recommended by the American Academy of Child and Adolescent Psychiatry 4